Gohibic, InflaRx and European Commission

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
InflaRx announces EC grants marketing authorization to Gohibic for ARDS
InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the
InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome
InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval
H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European Commission's approval of the company's treatment for COVID-19 related complications.
InflaRx’s Market Potential Bolstered by EU Approval of Gohibic
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay
InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress
InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress. The European Commission granted marketing authorization under exceptional circumstances for Gohibic,
Hosted on MSN21h
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...
InflaRx: Strategic Buy Rating Amidst Regulatory Milestones and Promising Pipeline
Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...
Yahoo Finance2mon
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Under the terms of GOHIBIC’s approval in the EU, which is anticipated early next year, InflaRx will provide annual updates to EMA on the previously announced clinical platform study planned by the ...